Comprehensive Analysis of Mutations in the Skeletal Muscle Ryanodine Receptor (RyR1).
MetadataShow full item record
General Abstract ---------------------- Patients born with mutations in the skeletal muscle ryanodine receptor (RyR1) suffer from muscular dysfunction associated with significant morbidity. Previous research has elucidated the pathophysiology of the disease and structure of the receptor, yet we are lacking in our understanding of the relationship between specific mutations in correlation to specific clinical manifestations. Currently, clinicians advise their patients to screen for RyR1 mutations yet when the results are returned positive—clinicians fail to determine the outcome in regard to precautions and prognosis. A comprehensive database, including all known RyR1 mutations documented in the literature and by international collaborators, was created to study the link between specific mutations and its clinical manifestations. In this project, the database has been utilized to identify specific regions in the receptor that can be associated with significant morbidity. ---------------------- Scientific Abstract ---------------------- Mutations in the ryanodine receptor (RyR1) are associated with malignant hyperthermia (MH) and RyR1-related myopathy. These mutations exhibit phenotypic and clinical variability, complicating the ability to assign pathogenicity. While gene sequencing is widely available, it has become difficult to determine whether or not variants are pathogenic. Over the past few decades, hundreds of patients have been reported in the literature along with their RyR1 variants. Our goal was to comprehensively review and organize all the clinical, genetic, and bioinformatics data from the literature and individual testing centers into an easily searchable database. This would make it possible to identify features of diseased and benign variants that can be used to predict outcome of unknown variants. Genetic and clinical data were obtained from PubMed and international collaborators. All together, we identified 1094 unique variants from 2265 patients with clinical suspicion for RyR1-related myopathy or malignant hyperthermia. The data was organized into a comprehensive, easily searchable database, along with 255 bioinformatics related data points for each variant. The availability of an easily searchable database that organizes genetic, clinical, bioinformatics, and structural data will help clinicians and scientists diagnose and treat patients suffering from these conditions. The database can be populated with data from different laboratories and incorporate highresolution cryo-EM structural spatial localization information, in-vitro and ex-vivo functional data, and patient clinical data. Eventually, it will help predict the functional effects of any RyR1 mutation and will provide investigators with a powerful tool for understanding the pathophysiology of a specific patient’s disease process and for designing personalized therapies.
The file is restricted for YU community access only. Mentor: Professor Radhashree Maitra, Department of Biology
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
Showing items related by title, author, creator and subject.
Flatow, Elie (Yeshiva College, 2016-05)Thyroid cancer is the most common endocrine malignancy, with an incidence that has been rising rapidly since the early 1990’s, and is the fastest increasing cancer in both men and women1 . An estimated 64,300 cases are ...
Ratner, Chana (Stern College for Women, 2016-05-24)In 1994, Dr. May-Claire King and her research team at the University of Washington, discovered a region of DNA that was associated with breast cancer and which soon became identified as the BRCA1 gene. A year later another ...
Shifteh, David (New York, NY: Yeshiva College. Yeshiva University., 2020-05)Abstract Colorectal cancer (CRC) is the third most commonly occurring cancer globally. One of the current therapies used in CRC treatment is the anti-epidermal growth factor receptor (anti- EGFR) monoclonal antibody, ...